Dashboard
Manage Tickers

ABBV


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

live-on-cnbc-rob-sechan-announces-bought-more-abbvie
Live On CNBC, Rob Sechan Announces Bought ...
10/24/2025 16:30:49

qualcomm-aptiv-palo-alto-and-a-health-care-stock-on-cnbcs-final-trades
Qualcomm, Aptiv, Palo Alto And A Health Ca...
10/22/2025 12:17:16

Jason Snipe stays long on AbbVie (ABBV). Guggenheim analyst raises price target. QUALCOMM (QCOM) picked by Jim Lebenthal. Steph...

Core News & Articles
CNBC Halftime Report Final Trades: Palo Al...
10/21/2025 17:01:52

guggenheim-maintains-buy-on-abbvie-raises-price-target-to-242
Guggenheim Maintains Buy on AbbVie, Raises...
10/20/2025 12:34:56

Guggenheim analyst Vamil Divan maintains AbbVie (NYSE:ABBV) with a Buy and raises the price target from $227 to $242.

abbvie-announced-topline-results-from-the-phase-3b4-head-to-head-select-switch-study-evaluating-the-efficacy-and-safety-of-upadacitinib-says-upadacitinib-outperforms-adalimumab-in-study-achieves-key-efficacy-endpoints-with-no-new-safety-risks
AbbVie Announced Topline Results From The ...
10/20/2025 12:10:56

Upadacitinib demonstrated superiority versus adalimumab for primary endpoint of achieving low disease activity (DAS28-CRP≤3.2) ...

raymond-james-reiterates-outperform-on-abbvie-raises-price-target-to-250
Raymond James Reiterates Outperform on Abb...
10/17/2025 16:07:17

Raymond James analyst Gary Nachman reiterates AbbVie (NYSE:ABBV) with a Outperform and raises the price target from $236 to ...

amazon-abbvie-datadog-and-a-financial-stock-cnbcs-final-trades
Amazon, AbbVie, Datadog And A Financial St...
10/14/2025 12:17:04

Analysts discuss stock performance and potential of AbbVie Inc, Amazon, Sixth Street Specialty Lending, and Datadog. Check out ...

if-you-invested-100-in-abbvie-stock-10-years-ago-you-would-have-this-much-today
If You Invested $100 In AbbVie Stock 10 Ye...
10/13/2025 21:00:34

Core News & Articles
CNBC Halftime Report Final Trades: AbbVie,...
10/13/2025 17:01:06

abbvie-says-fda-approves-snda-that-updates-indication-statement-for-rinvoq-for-treatment-of-adults-with-uc-and-cd
AbbVie Says FDA Approves sNDA That Updates...
10/13/2025 15:00:29

-        Updated indication allows the use of RINVOQ® (upadacitinib) prior to the use of tumor necrosis factor (TNF) blocking a...

abbvie-to-present-new-adc-data-at-esmo-congress-2025-highlighting-temab-a-abbv-706-and-emrelis-in-difficult-to-treat-tumors
AbbVie To Present New ADC Data At ESMO Con...
10/13/2025 11:18:16

New data from telisotuzumab adizutecan (Temab-A) and ABBV-706 across pancreatic, colorectal, and solid tumors, highlight progre...

piper-sandler-maintains-overweight-on-abbvie-raises-price-target-to-284
Piper Sandler Maintains Overweight on AbbV...
10/10/2025 12:38:43

Piper Sandler analyst Christopher Raymond maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $2...

Core News & Articles
A Congress Member Sold Up To $300K In A.O....
10/08/2025 15:00:28

abbvies-botox-shows-improvement-in-movement-disorder-study
AbbVie's Botox Shows Improvement In Moveme...
10/06/2025 14:54:17

AbbVie's Phase 2 ELATE trial shows onabotulinumtoxinA improves tremor scores and meets all endpoints, offering a new option...

abbvies-botox-meets-primary-and-all-secondary-endpoints-in-phase-2-elate-trial-for-upper-limb-essential-tremor
AbbVie's BOTOX Meets Primary And All Secon...
10/06/2025 13:06:06

OnabotulinumtoxinA (BOTOX®) met the primary endpoint in the Phase 2 trial, demonstrating a statistically significant improvemen...

abbvie-expects-q3-earnings-to-include-27b-iprd-expense-q3-adj-eps-guidance-range-is-174---178-sees-fy25-adj-eps-guidance-range-including-iprd-impact-is-1038---1058
AbbVie Expects Q3 Earnings To Include $2.7...
10/03/2025 20:14:48

Reported GAAP earnings and adjusted non-GAAP earnings for the third quarter of 2025 are expected to include acquired IPR&D ...

b-of-a-securities-maintains-neutral-on-abbvie-raises-price-target-to-251
B of A Securities Maintains Neutral on Abb...
10/03/2025 13:16:56

B of A Securities analyst Geoff Meacham maintains AbbVie (NYSE:ABBV) with a Neutral and raises the price target from $220 to...

what-does-the-market-think-about-abbvie-inc
What Does the Market Think About AbbVie Inc?
10/03/2025 13:00:44

reported-earlier-calico-life-sciences-abbvie-announce-joint-developed-abbv-cls-628-monoclonal-antibody-gets-us-fdas-fast-track-designation-for-autosomal-dominant-polycystic-kidney-disease
Reported Earlier: Calico Life Sciences, Ab...
10/02/2025 16:53:21

Calico Life Sciences LLC (Calico), a biotechnology organization focused on aging and age-related diseases and founded by Alphab...

Core News & Articles
10 Health Care Stocks Whale Activity In To...
10/01/2025 17:35:33

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION